Gemoscan Canada, Inc. (Gemoscan) is engaged in the provision of products and solutions to the food intolerance market. Gemoscan owns and markets the Hemocode System, which is a lifestyle solution that with a blood test detects and provides solutions for the treatment of food intolerances. Its market segments include consumers, which include treatment seekers, and health and diet conscious adults; practitioners and administrators, such as medical doctors, naturopaths, dieticians, nutritionists, homeopaths and chiropractors, clinics and health clubs; business to business, and retail, which includes drugs and grocery stores, and in-store health clinics. Gemoscan�s property includes USPTO 11/364,273 chemiluminescence technology. Its Hemocode product is sold to healthcare practitioners, pharmacies, insurance companies, specialty retail and service and Internet. The Hemocode System combines a blood test with an analysis software, generating reports and recipe books.